Physician profile
Haidong Yang
NPI 1427303536
$2,516.36
in general payments reported to CMS, 2019-2025
17 companies · $689 in 2025
The $689 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $153 · 2021: $147 · 2022: $370 · 2023: $116 · 2024: $584 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,388.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $377.18 | 2022-2025 | Rocklatan, Tryptyr, Rhopressa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $309.79 | 2019-2021 | |
| Amgen INC. | $287.18 | 2024-2025 | Tepezza |
| Abbvie INC. | $256.12 | 2024-2025 | |
| Aerie Pharmaceuticals, INC. | $229.91 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $223.36 | 2019-2025 | Cequa, Xelpros |
| Bausch & Lomb Americas INC. | $183.07 | 2022-2024 | Miebo, Xiidra, Vyzulta |
| Genentech USA, INC. | $152.91 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $147.16 | 2025 | Xdemvy |
| Shire North American Group INC | $72.92 | 2019 | |
| Oyster Point Pharma, INC. | $66.05 | 2022-2024 | Ryzumvi, Tyrvaya |
| Dompe US, INC. | $51.85 | 2022-2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $44.34 | 2025 | Acthar |
| Allergan, INC. | $41.96 | 2020-2021 | |
| Synergeyes, INC. | $32.93 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $20.00 | 2023 | Tepezza |
| Astellas Pharma US INC | $19.63 | 2024 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haidong Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.